Meghalaya: IDSP issues advisory asking people to get hospital treatment at first sign of GBS
Guillain-Barre Syndrome
(GBS) to tackle any potential outbreak.
The advisory was issued on Friday night after GBS was detected in Pune recently.
GBS is a rare neurological disorder in which the immune system attacks the peripheral nerves, often after infections such as respiratory illnesses, gastroenteritis, dengue or Zika virus.
Early symptoms include weakness, tingling or numbness starting in the legs, difficulty walking or climbing stairs, loss of balance or coordination, and in severe cases, trouble breathing, swallowing or speaking -- which require urgent medical care.
The advisory recommends avoiding self-medication, maintaining hygiene, steering clear of contaminated or raw food, protection against mosquito bites in dengue or Zika-prone areas, and eating nutritious food to strengthen immunity.
The recent GBS outbreak in Pune, Maharashtra, has heightened concerns among public health authorities at both the state and central levels.
Officials have called on the public to remain vigilant, adopt preventive measures and ensure timely medical intervention. PTI
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
a minute ago
- Time of India
Pfizer launches next-gen vaccine for pneumococcal disease
Pfizer has introduced its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, offering protection against 20 serotypes responsible for a majority of pneumococcal diseases. This single-dose vaccine provides timely and proactive protection for all adults, including those with chronic conditions, potentially eliminating the need for a second dose. Tired of too many ads? Remove Ads Drug firm Pfizer on Monday said it has launched its next-generation 20-valent pneumococcal conjugate vaccine ( PCV20 ) for adults in vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease , it said in a enables timely and proactive protection for all adults, including those living with chronic conditions, it will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker said."We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country," Pfizer MD Meenakshi Nevatia said. PTI
Time of India
an hour ago
- Time of India
Meet Adam Kovalčík: Teen scientist whose breakthrough could slash the costs of lifesaving drugs for Ebola, COVID-19 and more
Image credits: Getty Images (Representative Image) A 19-year-old from Slovakia was flying to an international science competition in Ohio, with an idea that he didn't expect to win big, but loved enough to showcase to the world. Adam Kovalčík, a teen from a small village in a European country, not only walked away with the George D. Yancopoulos Innovator Award but also a $100,000 top prize for his breakthrough idea that could slash the cost of antiviral drugs. Adam Kovalčík's innovative method Image credits: Getty Images According to a Business Insider report, Kovalčík created a simplified drug production method using corn husks in place of the most costly ingredients. The young prodigy had aimed to make galidesivir cheaper and faster to produce. The drug targets RNA viruses, including Ebola, Zika and COVID-19. He replaced the standard beginning materials with furfuryl alcohol, a compound that is derived from corn waste. Additionally, rather than assembling the molecule in multiple stages, he formed the core sugar in seven reactions, developing a shorter 10-step method from the conventional 15. This cuts the production time from nine to five days and reduces the cost per gram from $75 to just $12.50. What lies ahead? While his method would need to go through clinical trials before any wide-scale applications, the Regeneron judges were impressed and described his presentation as airtight. "This could be a huge step to help prevent some of these RNA viruses," said Chris RoDee, chemist and chair of the judging committee and retired patent examiner. "I cannot describe this feeling," Kovalčík told Business Insider after the live ceremony, adding that he was surprised to win, especially coming from a small Slovakian village. After the competition, he filed a preliminary patent and returned to his university lab to continue refining the synthesis. According to early computer modelling, one new molecule from his work may bind more effectively to viral enzymes than galidesivir. Kovalčík is also working on a side project that turns corn waste into fragrance compounds. His work is a part of a growing movement of scientists who are rethinking food waste to create big breakthroughs from small labs.
News18
2 hours ago
- News18
Pfizer launches next-gen vaccine for pneumococcal disease
Agency: PTI New Delhi, Aug 11 (PTI) Drug firm Pfizer on Monday said it has launched its next-generation 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. The vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease, it said in a statement. It enables timely and proactive protection for all adults, including those living with chronic conditions, it added. PCV20 will be available as a single-shot vaccine and those vaccinated with PCV20 may not need a second dose, the drug maker said. 'We believe this vaccine, with its broad coverage of 20 pneumococcal disease serotypes, will address the increasing need for adult immunisation in our country," Pfizer MD Meenakshi Nevatia said. PTI MSS MSS MR MR view comments First Published: August 11, 2025, 19:15 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
